The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
ErbB receptors: from oncogenes to targeted cancer therapies
Open accessAbstract
Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“In addition, ErbB-targeted therapeutic strategies have been shown to sensitize tumor cells to traditional chemotherapy and radiotherapy (5, 6).”
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 3×
“Erlotinib and gefitinib have been shown to have higher binding affinity to the sensitive mutant (L858R) than to WT EGFR or the T790M EGFR mutant (87, 115 ).”
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
A minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“Nagata et al. (100) discovered that patients with p185 her2/neu -express- ing breast cancer who also had PTEN deficiency, which happens in 48% of breast cancers (101), had a substantially lower response rate to trastuzumab than did patients with p185 her2/neu -expressing breast cancer who had no PTEN deficiency.”
Dimerization of cell surface receptors in signal transduction
Heldin, C.-H. (1995) · Cell · doi:10.1016/0092-8674(95)90404-2 · Cited by 1,634
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Self-citationA Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Crystal Structures of c-Src Reveal Features of Its Autoinhibitory Mechanism
Xu, W., Doshi, A., Lei, M., Eck, M. J., & Harrison, S. C. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80356-1 · Cited by 870
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., & Aaronson, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9193 · Cited by 737
A quantitative protein interaction network for the ErbB receptors using protein microarrays
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006) · Nature · doi:10.1038/nature04177 · Cited by 727
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., & Shoyab, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1746 · Cited by 713
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
Chen, W. S., Lazar, C. S., Poenie, M., Tsien, R. Y., Gill, G. N., & Rosenfeld, M. G. (1987) · Nature · doi:10.1038/328820a0 · Cited by 592
A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
Carraway, K. L., & Cantley, L. C. (1994) · Cell · doi:10.1016/0092-8674(94)90564-9 · Cited by 587
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin.
Shih, C., Shilo, B. Z., Goldfarb, M. P., Dannenberg, A., & Weinberg, R. A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.11.5714 · Cited by 486
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor
Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., & Kuriyan, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80357-3 · Cited by 430
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989) · Nature · doi:10.1038/339230a0 · Cited by 423
Self-citationFry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 400
Self-citationIntermolecular association of the p185 protein and EGF receptor modulates EGF receptor function
Wada, T., Qian, X., & Greene, M. I. (1990) · Cell · doi:10.1016/0092-8674(90)90697-d · Cited by 361
Self-citationVarley, J. M., Swallow, J. E., Brammar, W. J., Whittaker, J. L., & Walker, R. A. (1987) · PubMed · Cited by 360
van de Vijver, M., van de Bersselaar, R., Devilee, P., Cornelisse, C., Peterse, J., & Nusse, R. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.5.2019 · Cited by 330
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C. R., HARRIS, R. A., Pagé, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., et al. (2001) · PubMed · Cited by 330
Shaw, E. G., Rosdhal, R., D'Agostino, R. B., Lovato, J., Naughton, M. J., Robbins, M. E., & Rapp, S. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3001 · Cited by 326
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann, C. I., & Weinberg, R. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03044.x · Cited by 315
Chromosomal passengers: the four-dimensional regulation of mitotic events
Vagnarelli, P., & Earnshaw, W. C. (2004) · Chromosoma · doi:10.1007/s00412-004-0307-3 · Cited by 314
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., & Greene, M. I. (1989) · Cell · doi:10.1016/0092-8674(89)90843-x · Cited by 309
Self-citationLoss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer
Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 294
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2007) · Cancer · doi:10.1002/cncr.22402 · Cited by 281
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F., & Daidone, M. G. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8518-3 · Cited by 275
Hirsch, F. R., Varella-Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 268
Epidermal growth factor receptor tyrosine kinase
Ward, W. H. J., Cook, P. N., Slater, A. M., Davies, D. H., Holdgate, G. A., & Green, L. R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90042-6 · Cited by 261
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 257
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., & Schwall, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2531 · Cited by 251
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.
Drebin, J. A., Link, V. C., Weinberg, R. A., & Greene, M. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.23.9129 · Cited by 233
Self-citationOncogenes and the strategy of growth factors
Baserga, R. (1994) · Cell · doi:10.1016/0092-8674(94)90023-x · Cited by 230
Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-22-cor1 · Cited by 230
Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.
Siegel, P. M., Dankort, D. L., Hardy, W. R., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7068 · Cited by 213
Klos, K. S., Wyszomierski, S. L., Sun, M., Tan, M., Zhou, X., Li, P., Yang, W., Yin, G., Hittelman, W. N., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4559 · Cited by 201
Park, B.-W., Zhang, H.-T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O'Rourke, D. M., Greene, M. I., et al. (2000) · Nature Biotechnology · doi:10.1038/72651 · Cited by 199
Self-citationDNA Contents of Chromosome Ph 1 and Chromosome 21 in Human Chronic Granulocytic Leukemia
Rudkin, G. T., Hungerford, D. A., & Nowell, P. C. (1964) · Science · doi:10.1126/science.144.3623.1229 · Cited by 198
Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., Sato, M., & Sato, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0491 · Cited by 195
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M., & Leahy, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507591102 · Cited by 192
Qian, X., LeVea, C., Freeman, J. K., Dougall, W. C., & Greene, M. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1500 · Cited by 173
Self-citationXia, W., Bisi, J., Strum, J. C., Liu, L.-H., Carrick, K., Graham, K. M., Treece, A. L., Hardwicke, M. A., Dush, M. K., Liao, Q., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2000 · Cited by 165
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
Drebin, J. A., Stern, D. F., Link, V. C., Weinberg, R. A., & Greene, M. I. (1984) · Nature · doi:10.1038/312545a0 · Cited by 163
Self-citationYe, D., Mendelsohn, J. M., & Fan, Z. (1999) · Oncogene · doi:10.1038/sj.onc.1202319 · Cited by 151
Xia, W., Husain, I., Liu, L.-H., Bacus, S. S., Saini, S., Spohn, J., Pry, K. J., Westlund, R. E., Stein, S. H., & Spector, N. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2101 · Cited by 148
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
Cohenuram, M. K., & Saif, M. W. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32800feecb · Cited by 141
Crystal Structure and Mutagenic Analysis of the Inhibitor-of-Apoptosis Protein Survivin
Muchmore, S. W., Chen, J., Jakob, C. G., Zakula, D., Matayoshi, E. D., Wu, W., Zhang, H., Li, F., Ng, S., & Altieri, D. C. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00018-6 · Cited by 132
Self-citationSiegel, P. M., & Muller, W. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.8878 · Cited by 132
Tan, M., Lan, K., Yao, J., Lu, C., Sun, M., Neal, C. L., Lü, J., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2747 · Cited by 129
Solution Structure of Human Survivin and Its Binding Interface with Smac/Diablo
Sun, C. C., Nettesheim, D. G., Liu, Z., & Olejniczak, E. T. (2004) · Biochemistry · doi:10.1021/bi0485171 · Cited by 109
Berezov, A., Zhang, H., Greene, M. I., & Murali, R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000527m · Cited by 108
Self-citationCampos, S. M., Hamid, O., Seiden, M. V., Oza, A. M., Plante, M., Potkul, R. K., Lenehan, P. F., Kaldjian, E. P., Varterasian, M. L., Jordan, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.091 · Cited by 106
Radiosensitization of Human Melanoma Cells by Ribozyme-Mediated Inhibition of Survivin Expression
Pennati, M., Binda, M., Colella, G., Folini, M., Villa, R., Daidone, M. G., Zaffaroni, N., & Citti, L. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12082.x · Cited by 97
Montagna, C., Andrechek, E. R., Padilla‐Nash, H. M., Muller, W. J., & Ried, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205146 · Cited by 94
Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics
Berezov, A., Chen, J., Liu, Q., Zhang, H., Greene, M. I., & Murali, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202880200 · Cited by 93
Self-citationSpiridon, C., Guinn, S. E., & Vitetta, E. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0549 · Cited by 91
Yoshimura, N., Kudoh, S., Kimura, T., Mitsuoka, S., Matsuura, K., Hirata, K., Matsui, K., Negoro, S., Nakagawa, K., & Fukuoka, M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.10.006 · Cited by 81
O’Rourke, D. M., Kao, G. D., Singh, N., Park, B., Muschel, R. J., Wu, C.-J., & Greene, M. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10842 · Cited by 76
Self-citationA sensitive and high-throughput assay to detect low-abundance proteins in serum
Zhang, H., Cheng, X., Richter, M., & Greene, M. I. (2006) · Nature Medicine · doi:10.1038/nm1378 · Cited by 72
Self-citationFantin, V. R., Berardi, M. J., Babbe, H., Ventosa-Michelman, M., Manning, C. M., & Leder, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0395 · Cited by 57
Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function
Neve, R. M., Nielsen, U. B., Kirpotin, D. B., Poul, M., Marks, J. D., & Benz, C. C. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4104 · Cited by 55
Drebin, J. A., Link, V. C., & Greene, M. I. (1988) · PubMed · Cited by 53
Self-citationA Novel Mechanism of Resistance to Epidermal Growth Factor Receptor Antagonism In vivo
Rajput, A., Koterba, A. P., Kreisberg, J. I., Foster, J. M., Willson, J. K. V., & Brattain, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2773 · Cited by 52
Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185 Monoclonal Antibodies
Zhang, H., Wang, Q., Montone, K. T., Peavey, J. E., Drebin, J. A., Greene, M. I., & Murali, R. (1999) · Experimental and Molecular Pathology · doi:10.1006/exmp.1999.2266 · Cited by 44
Self-citationEGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway
Wang, Q., & Greene, M. I. (2005) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.05.002 · Cited by 40
Self-citationWada, T., Myers, J. N., Kokai, Y., et al. (1990) · PubMed · Cited by 35
Masuda, K., Richter, M., Song, X., Berezov, A., Masuda, K., Murali, R., Greene, M. I., & Zhang, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209745 · Cited by 33
Self-citationMom, C. H., Eskens, F. A. L. M., Gietema, J. A., Nooter, K., Jonge, M. J. D., Amelsberg, A., Huisman, H., Stopfer, P., de Vries, E. G. E., & Verweij, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3025 · Cited by 11
Cited by
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Self-citationTargeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
SERS Nanoparticles in Medicine: From Label-Free Detection to Spectroscopic Tagging
Lane, L. A., Qian, X., & Nie, S. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00265 · Cited by 873
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Metadata
- Authors
- Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-08-01
- Volume
- 117
- Issue
- 8
- Pages
- 2051-2058
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2071289226
- Cited by
- 574
- References
- 110
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.